超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

奧地利BIOCRATES Life Sciences AG
奧地利BIOCRATES生命科學(xué)公司是一家致力于代謝生物技術(shù)，產(chǎn)品應(yīng)用于疾病檢查，食品、藥品檢測的前沿技術(shù)開發(fā)公司。
該公司的研究和開發(fā)的重點(diǎn)在于兩大支柱：一個(gè)是強(qiáng)大的生物標(biāo)志物識別和面板，幫助識別疾病的危險(xiǎn)，診斷疾病的驗(yàn)證，評估疾病的嚴(yán)重程度，指導(dǎo)治療。 Biocrates制定了全面的生物標(biāo)志物的管道，包括從慢性疾病，如Ⅱ型糖尿病，適應(yīng)癥，以急性事件，如中風(fēng)。
另一種是支持發(fā)展生物標(biāo)志物面板，幫助評估一個(gè)新的藥物如何在人體內(nèi)工作，并確定患者最有可能回應(yīng)的待遇或至少可能遭受的副作用等研究機(jī)構(gòu)。這種生物標(biāo)志物，它正成為部分和-有針對性的治療方法設(shè)計(jì)的一部分，被稱為同伴診斷。
這種創(chuàng)新的，全面集成的代謝組學(xué)技術(shù)平臺是基于質(zhì)譜法，使一類生物分子有關(guān)的各種系統(tǒng)的量化在廣泛的樣本，從血液和血清細(xì)胞或組織。

Founded in 2002, Biocrates is dedicated to further developing and harnessing a relatively young technology referred to as metabolomics. The company’s research and development focus rests on two pillars:

One is the identification and validation of powerful biomarker panels that help identify disease risk, diagnose diseases, assess disease severity, and guide treatment. Biocrates has developed a comprehensive biomarker pipeline, covering indications from chronic disorders, such as type II diabetes, to acute events, such as stroke.
The other is to support other research organizations in developing biomarker panels that help assess how a new drug works in the body and identify patients most likely to respond to a treatment or least likely to suffer side effects. Such biomarkers, which are becoming part-and-parcel of the design of targeted therapies, are referred to as companion diagnostics.
This innovative, fully integrated technology platform for metabolomics is based on mass spectrometry, enabling the systematic quantification of a wide range of biologically relevant molecule classes in a wide range of samples, from blood and serum to cells or tissues.


BIOCRATES Life Sciences AG, a leading company in the field of diagnostic biomarker research.
Biomarkers are rapidly becoming the main drivers of innovation in the 21st century. Because they improve the potential to tailor treatment to the specific needs of individual patients, they are a critical prerequisite to personalized medicine.
Biocrates identifies and quantifies endogenous metabolites in body fluid or tissue samples and develops them into powerful biomarkers. By focusing on metabolites, we look at the functional endpoints of diseases and drug action—a technology called metabolomics.
Cutting-edge biomarker research stands to benefit everyone.

Research organizations will be able to enrich their diagnostics and drug development programs and save costs by better targeting their projects.
Physicians will be able to predict disease risk more reliably, establish diagnoses earlier, and tailor treatments more individually.
Patients will benefit from treatments that are more efficacious and have fewer side effects.
Investors can expect to be part of our cutting-edge science combined with sustained value creation.
Biocrates—bringing society one step closer to the goal of personalized medicine.